Compile Data Set for Download or QSAR
Report error Found 26539 for UniProtKB: P01116
TargetGTPase KRas(Human)
University of California San Francisco

Curated by ChEMBL
LigandPNGBDBM50579601(CHEMBL4858364 | US11453683, Example 252 | US202302...)
Affinity DataKd: <0.000200nMAssay Description:Binding affinity to KRAS (unknown origin) assessed as dissociation constantMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/23/2023
Entry Details
PubMed
TargetGTPase KRas(Human)
University of California San Francisco

Curated by ChEMBL
LigandPNGBDBM717622(US20250034173, Example 13)
Affinity DataKd: <0.00100nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM617349(US20230279025, Example 465)
Affinity DataIC50: 0.00100nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2023
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM573400(US11453683, Example 259 | US20230279025, Example 4...)
Affinity DataIC50: 0.00200nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2023
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM50579601(CHEMBL4858364 | US11453683, Example 252 | US202302...)
Affinity DataIC50: 0.00200nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2023
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM617355(US20230279025, Example 468)
Affinity DataIC50: 0.00200nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2023
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM617357(US20230279025, Example 469)
Affinity DataIC50: 0.00200nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2023
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM617323(US20230279025, Example 452 | US20230279025, Exampl...)
Affinity DataIC50: 0.00200nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2023
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM617363(US20230279025, Example 482)
Affinity DataIC50: 0.00200nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2023
Entry Details
US Patent

TargetGTPase KRas(Human)
University of California San Francisco

Curated by ChEMBL
LigandPNGBDBM717614(US20250034173, Example 2)
Affinity DataKd:  0.00400nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM617351(US20230279025, Example 466)
Affinity DataIC50: 0.00600nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2023
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM617347(US20230279025, Example 464)
Affinity DataIC50: 0.00700nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2023
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM617345(US20230279025, Example 463)
Affinity DataIC50: 0.0120nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2023
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717622(US20250034173, Example 13)
Affinity DataKd:  0.0170nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717614(US20250034173, Example 2)
Affinity DataKd:  0.0190nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM629510(US20230339981, Example 198)
Affinity DataIC50: 0.0200nMAssay Description:Compounds were tested for binding to GDP-loaded KRAS G12D in a 384-well assay format using a TR-FRET probe displacement assay in buffer consisting of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706700(US20240383922, Example 22-2)
Affinity DataIC50: 0.0200nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706700(US20240383922, Example 22-2)
Affinity DataIC50: 0.0200nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM629513(US20230339981, Example 201)
Affinity DataIC50: 0.0200nMAssay Description:Compounds were tested for binding to GDP-loaded KRAS G12D in a 384-well assay format using a TR-FRET probe displacement assay in buffer consisting of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM717620(US20250034173, Example 11)
Affinity DataKd:  0.0240nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM617339(US20230279025, Example 460)
Affinity DataIC50: 0.0270nMAssay Description:This Example illustrates that exemplary compounds of the present invention inhibit the phosphorylation of ERK downstream of KRAS G12D. AGS cells (ATC...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/17/2023
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706571(US20240383915, Example 100a)
Affinity DataIC50: 0.0300nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas(Human)
University of California San Francisco

Curated by ChEMBL
LigandPNGBDBM706571(US20240383915, Example 100a)
Affinity DataIC50: 0.0300nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM50628058(US20240327434, Compound 9-p1 | CHEMBL5439556)
Affinity DataKd:  0.0300nMAssay Description:Biotinylated Avi-KRAS-WT or Avi-KRAS-G12D was diluted to 20 μg/mL with 1x HBS-P+(Cat. #BR1006-71) buffer containing 100 mM MgCl2, and then flowe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
US Patent

TargetGTPase KRas(Human)
University of California San Francisco

Curated by ChEMBL
LigandPNGBDBM706700(US20240383922, Example 22-2)
Affinity DataIC50: 0.0300nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM717613((General Method A): (8aS)-5-(6-chloro-5-cyclopropy...)
Affinity DataKd:  0.0310nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas(Human)
University of California San Francisco

Curated by ChEMBL
LigandPNGBDBM717613((General Method A): (8aS)-5-(6-chloro-5-cyclopropy...)
Affinity DataKd:  0.0380nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706507(US20240383915, Example 48)
Affinity DataIC50: 0.0400nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM629509(US20230339981, Example 197)
Affinity DataIC50: 0.0400nMAssay Description:Compounds were tested for binding to GDP-loaded KRAS G12D in a 384-well assay format using a TR-FRET probe displacement assay in buffer consisting of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684846(4-(10-((R)-1-(2-aminopyridin-3-yl)ethyl)- 4-fluoro...)
Affinity DataIC50: 0.0400nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684825(4-(10-((R)-1-(2-aminopyridin-3-yl)ethyl)- 4-fluoro...)
Affinity DataIC50: 0.0400nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM629518(US20230339981, Example 206)
Affinity DataIC50: 0.0400nMAssay Description:Compounds were tested for binding to GDP-loaded KRAS G12D in a 384-well assay format using a TR-FRET probe displacement assay in buffer consisting of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM706670(US20240383922, Example 6-23)
Affinity DataIC50: 0.0400nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM717614(US20250034173, Example 2)
Affinity DataKd:  0.0410nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684823(3-((R)-1-(5-(5-amino-4-fluoro-3-methyl-2- (trifluo...)
Affinity DataIC50: 0.0450nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM717613((General Method A): (8aS)-5-(6-chloro-5-cyclopropy...)
Affinity DataKd:  0.0480nMAssay Description:Binding measurements were performed in parallel sets of either WT/G12D/G12C/G12V KRAS or WT K/H/N RAS proteins in GDP and/or GTPγS-loaded forms.Biaco...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
6/5/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706612(US20240383915, Example 133c)
Affinity DataIC50: 0.0500nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM629381(US20230339981, Example 68)
Affinity DataIC50: 0.0500nMAssay Description:Compounds were tested for binding to GDP-loaded KRAS G12D in a 384-well assay format using a TR-FRET probe displacement assay in buffer consisting of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706594(US20240383915, Example 119)
Affinity DataIC50: 0.0500nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas(Human)
University of California San Francisco

Curated by ChEMBL
LigandPNGBDBM706661(US20240383922, Example 6-14)
Affinity DataIC50: 0.0500nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM629505(US20230339981, Example 193)
Affinity DataIC50: 0.0500nMAssay Description:Compounds were tested for binding to GDP-loaded KRAS G12D in a 384-well assay format using a TR-FRET probe displacement assay in buffer consisting of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706535(US20240383915, Example 75a)
Affinity DataIC50: 0.0500nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706551(US20240383915, Example 88)
Affinity DataIC50: 0.0500nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM647873(US20240025919, Compound 104)
Affinity DataIC50: 0.0500nMAssay Description:Biochemical compound potencies are assessed by evaluating inhibition of SOS1I-mediated nucleotide exchange in KRAS G121D. In this assay, the SOS1-pro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2024
Entry Details
US Patent

TargetGTPase KRas [G12D](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM629512(US20230339981, Example 200)
Affinity DataIC50: 0.0500nMAssay Description:Compounds were tested for binding to GDP-loaded KRAS G12D in a 384-well assay format using a TR-FRET probe displacement assay in buffer consisting of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/10/2023
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684879(3-((R)-1-(5-(5-amino-3,4-difluoro-2-(trifluorometh...)
Affinity DataIC50: 0.0500nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetGTPase KRas [G12C](Human)
Pfizer

US Patent
LigandPNGBDBM706670(US20240383922, Example 6-23)
Affinity DataIC50: 0.0500nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706670(US20240383922, Example 6-23)
Affinity DataIC50: 0.0500nMAssay Description:Compounds were tested for binding to GDP-loaded wild-type KRAS (WT), KRAS-G12C, KRAS-G12D, and KRAS-G12V in a 384-well assay format using a TR-FRET p...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684840(3-((R)-1-((S)-5-(3-amino-2-chloro-5-methyl-6-(trif...)
Affinity DataIC50: 0.0500nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetGTPase KRas [G12V](Human)
Gilead Sciences

US Patent
LigandPNGBDBM706526(US20240383915, Example 66a)
Affinity DataIC50: 0.0500nMAssay Description:KRAS Biochemical Assay—BODIPY-GDP Exchange TR-FRET. Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/12/2025
Entry Details
US Patent

Displayed 1 to 50 (of 26539 total ) | Next | Last >>
Jump to: